- Industry Left Col
- Industry Right Col
What is ui developer role?
UI Developer Role
What is ui developer role?
The role of a User Interface (UI) developer is to provide the user interface solution to the end user, including the final look, feel and behaviour of the interface in different contexts. They role of a UI Developer is the transformational combination of the roles of both the Web Designer and the Web Developer.
The task of the Web Designer was to design and create a page without considering the functional aspects of the page. The page was then passed on to the Web Developer to add functionalities to it. But the changing nature of the industry and client requirements to have developers capable enough of adding dynamic content to web pages, lead to the evolution of the role of web designers into UI developers.
UI Developers see a website as a collection of assets applied to the pages and are concerned with the overall user experience. Their role is basically concerned with the following aspects of User experience:
- Aesthetics (Look and feel) of the UI
- Security capabilities
HR Executives today are under significant pressure to demonstrate their contribution to their organization’s strategic goals. They are now looking for opportunities to take a business leadership role that goes beyond the people strategy. There is both the desire and the need to demonstrate and improve the value delivered by HR. Critically this change is occurring at a time of intense competition and globalization. In addition the impact of the so called “Generation Y” and developments in social uses of technology are driving the need for different approaches in workforce management and organizational structures.
iGovern™ Unemployment Insurance
The customer is a US-based Integrated Logistics provider with operations spread across the globe.
UI Strategy Execution for a Global Logistics Provider
The Food and Drug Administration Amendments Act (FDAAA) of 2007 signed on September 27, 2007 authorizes the Food and Drug Administration (FDA) to require manufacturers to submit a proposed Risk Evaluation and Mitigation Strategy (REMS) if the FDA determines that REMS is necessary to ensure that the benefits of the drug or biological product outweigh the risks. The act took effect on March 25, 2008 and it applies to applications submitted under Food and Drug Cosmetics Act (FDCA) subsection 505 (b) or (j) and applications submitted under section 351 of the Public Health. These applications are termed covered applications and refer to new drug applications (NDAs), abbreviated new drug applications (ANDAs) and biologic license applications (BLAs).